Biotech · Public company · Germantown, MD, US
Precigen, Inc.
Ticker PGEN · SEC CIK 0001356090
Track this companyFree. Adds Precigen, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials86 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline8
- Zopapogene imadenovec-drbaPhase 3 · Recurrent Respiratory Papillomatosis (RRP)ClinicalTrials.gov · fetched Nov 12, 2026
- PRGN-2009 plus PembrolizumabPhase 2 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- PRGN-2012 - Phase I; Dose Level 1Phase 2 · Recurrent Respiratory PapillomatosisClinicalTrials.gov · fetched Nov 12, 2026
- PRGN-2012 - Phase I; Dose Level 2Phase 2 · Recurrent Respiratory PapillomatosisClinicalTrials.gov · fetched Nov 12, 2026
- PRGN-2012 - Phase II; Dose Level 2Phase 2 · Recurrent Respiratory PapillomatosisClinicalTrials.gov · fetched Nov 12, 2026
- PRGN-3005 UltraCAR-T cellsPhase 1 · Platinum-Resistant Fallopian Tube CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PRGN-3006 T CellsPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Zopapogene imadenovec (Zopa)Recurrent Respiratory PapillomatosisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in ChildrenPHASE3 · NOT_YET_RECRUITING · started Dec 31, 2026ClinicalTrials.gov NCT07901738 · fetched Nov 12, 2026
- PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerPHASE2 · RECRUITING · started Nov 11, 2025ClinicalTrials.gov NCT06157151 · fetched Nov 12, 2026
- Zopa Retreatment and Vector Shedding in Adults With RRPPHASE4 · RECRUITING · started Jul 11, 2024ClinicalTrials.gov NCT06538480 · fetched Nov 12, 2026
- Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor MalignanciesPHASE1 · COMPLETED · started Jan 25, 2023ClinicalTrials.gov NCT05694364 · fetched Nov 12, 2026
- Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 16, 2021ClinicalTrials.gov NCT04724980 · fetched Nov 12, 2026
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSPHASE1 · ACTIVE_NOT_RECRUITING · started May 20, 2019ClinicalTrials.gov NCT03927261 · fetched Nov 12, 2026
- Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 30, 2019ClinicalTrials.gov NCT03907527 · fetched Nov 12, 2026
- Novel INXN-4001 Triple Effector Plasmid in Heart FailurePHASE1 · COMPLETED · started Apr 9, 2018ClinicalTrials.gov NCT03409627 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 24, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 25, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 25, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 17, 2025 · fetched Nov 12, 2026